08 September 2017 EMA/CAT/599328/2017 Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT) Draft agenda for the meeting on 06-08 September 2017

Chair: Martina Schüßler-Lenz; Vice-Chair: Ilona Reischl 06 September 2017, 10:00 – 18:30, room 02-A 07 September 2017, 09:00 – 18:30, room 02-A 08 September 2017, 09:00 – 12:00, room 02-A

Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised. Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

Table of contents 1.

Introduction

5

1.1.

Welcome and declarations of interest of members, alternates and experts ............ 5

1.2.

Adoption of agenda ................................................................................................ 5

1.3.

Adoption of the minutes ......................................................................................... 5

1.4.

August 2017 Written Procedure ............................................................................. 5

1.5.

Technical information ............................................................................................. 5

2.

Evaluation of ATMPs

2.1.

Opinions ................................................................................................................. 5

2.2.

Oral explanations ................................................................................................... 5

2.3.

Day 180 list of outstanding issues .......................................................................... 5

2.4.

Day 120 list of questions ........................................................................................ 5

2.4.1.

Haploidentical donor lymphocytes depleted of alloreactive T cells, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells- Orphan - EMEA/H/C/002397 ........................ 5

2.5.

Day 80 assessment reports .................................................................................... 6

2.6.

Update on ongoing initial applications .................................................................... 6

5

Axicabtagene ciloleucel – Orphan - EMA/H/0004480 ...................................................... 6 2.6.2.

Voretigene neparvovec - Orphan - EMEA/H/C/0004451 .................................................. 6

2.7.

New applications .................................................................................................... 6

2.8.

Withdrawal of initial marking authorisation application ......................................... 6

2.9.

Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 ............................................................................................................... 6

2.10.

GMP and GCP inspections requests ......................................................................... 7

2.11.

Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .......................................................... 7

2.11.1.

Zalmoxis – Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex in virus thymidine kinase (hsv-tk mut2); Orphan; EMEA/H/C/002801/II/0005/G ... 7

2.12.

Other Post-Authorisation Activities ........................................................................ 7

2.12.1.

Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan EMEA/H/C/003854/REC/010 ....................................................................................... 7

3.

Certification of ATMPs

3.1.

Opinion ................................................................................................................... 7

3.2.

Day 60 Evaluation Reports...................................................................................... 7

3.3.

New Applications .................................................................................................... 8

4.

Scientific Recommendation on Classification of ATMPs

4.1.

New requests – Appointment of CAT Coordinator ................................................... 8

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

7

8

Page 2/17

4.1.1.

Allogenic cardiopoietic cells derived from adipose tissue derived stem cells (ADSC) purified from healthy donor’s lipoaspirate – H0004911............................................................... 8

4.1.2.

Recombinant adeno-associated virus serotype 2/1 vector encoding human β-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta) – H0004906 ...................................... 8

4.1.3.

Adeno-associated virus (AAV) vector serotype 8 expressing human low-density lipoprotein receptor (hLDLR) - H0004905 ..................................................................................... 8

4.1.4.

Skin tissue – H0004907.............................................................................................. 8

4.1.5.

Autologous CD34+ cells, freshly isolated – H000 ........................................................... 8

4.1.6.

Autologous dental pulp stem cells (DPSC), freshly isolated – H000 .................................. 8

4.1.7.

Cultured dental pulp stem cells (DPSC) – H000 ............................................................. 9

4.2.

Day 30 ATMP scientific recommendation ................................................................ 9

4.2.1.

Allogeneic human glial-restricted precursors - H0004887/0001 ....................................... 9

4.2.2.

Allogeneic human glial-restricted precursors - H0004898/0001 ....................................... 9

4.2.3.

Nuclease-resistant, synthetic double-stranded, siRNA designed to temporarily inhibit the expression of the collagen-specific chaperone, HSP47 - H0004900/0001 .......................... 9

4.2.4.

Messenger RNA encoding immunostimulatory proteins caTLR4, CD40L and CD70 and tumour associated antigens (TAA) tyrosinase, gp100, MAGE A3, MAGE C2 and PRAME H0004899/0001 ........................................................................................................ 9

4.2.5.

Cultured viable chondrocytes in a 3D Hydrogel - H0004901/0001 .................................... 9

4.3.

Day 60 revised scientific recommendation (following list of questions) ............... 10

4.4.

Finalisation of procedure ...................................................................................... 10

4.5.

Follow-up and guidance ........................................................................................ 10

5.

Scientific Advice

5.1.

New requests – appointment of CAT Rapporteurs ................................................ 10

5.2.

CAT reports........................................................................................................... 10

5.3.

List of Issues ........................................................................................................ 10

5.4.

Finalisation of SA procedures ............................................................................... 10

6.

Pre-Authorisation Activities

6.1.

Pediatric investigation plans ................................................................................ 10

6.2.

ITF briefing meetings in the field of ATMPs .......................................................... 10

6.3.

Priority Medicines (PRIME) – Eligibility requests .................................................. 10

6.3.1.

Month 0 - Start of the procedure ............................................................................... 10

6.3.2.

Month 1 – Discussion of eligibility .............................................................................. 11

6.3.3.

Month 2 – Recommendation of eligibility..................................................................... 11

6.3.4.

Month 3 – Nomination of Rapporteurs ........................................................................ 11

7.

Organisational, regulatory and methodological matters

7.1.

Mandate and organisation of the CAT ................................................................... 11

7.1.1.

Strategic Review & Learning meeting – Tallinn, Estonia, 15-17 November 2017 ............. 11

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

10

10

11

Page 3/17

7.1.2.

Multinational Assessment Team (MNAT) concept: the next phase – broadening the concept to the post-authorisation phase ..................................................................................... 11

7.2.

Coordination with EMA Scientific Committees....................................................... 11

7.2.1.

Committee for Medicinal Products for Human Use (CHMP) ............................................ 11

7.2.2.

Pharmacovigilance Risk Assessment Committee (PRAC) ............................................... 11

7.3.

Coordination with EMA Working Parties/Working Groups/Drafting Groups ......... 12

7.3.1.

Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP) ........................................................ 12

7.4.

Cooperation within the EU regulatory network ..................................................... 12

7.5.

Cooperation with international regulators ............................................................ 12

7.5.1.

ATMP cluster teleconference with FDA, Health Canada and PMDA................................... 12

7.6.

CAT work plan ...................................................................................................... 12

7.6.1.

Expert meeting on adeno-associated viral vectors, 6 September 2017, EMA, London ....... 12

7.6.2.

Expert meeting on genome editing, EMA, 18 October 2017 ........................................... 12

7.6.3.

CAT 2017 work plan ................................................................................................. 12

7.6.4.

CAT 2018 work plan ................................................................................................. 13

7.7.

Planning and reporting ......................................................................................... 13

7.7.1.

Update on ongoing ATMP-related activities.................................................................. 13

7.8.

Others .................................................................................................................. 13

7.8.1.

Interaction with EBMT .............................................................................................. 13

8.

Any other business

13

9.

Explanatory notes

14

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 4/17

1. 1.1.

Introduction Welcome and declarations of interest of members, alternates and experts Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 06-08 September 2017. See September 2017 CAT minutes (to be published post-October 2017 CAT meeting).

1.2.

Adoption of agenda CAT agenda for the 06-08 September 2017 meeting

1.3.

Adoption of the minutes CAT minutes for the 12-14 July 2017 meeting

1.4.

August 2017 Written Procedure CAT minutes of the August 2017 Written Procedure

1.5.

Technical information

2.

Evaluation of ATMPs

2.1.

Opinions No items

2.2.

Oral explanations No items

2.3.

Day 180 list of outstanding issues No items

2.4.

Day 120 list of questions

2.4.1.

Haploidentical donor lymphocytes depleted of alloreactive T cells, donor Tlymphocytes depleted ex vivo of host alloreactive T-cells- Orphan EMEA/H/C/002397 Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 5/17

Scope: D120 List of questions Action: for adoption

2.5.

Day 80 assessment reports No items

2.6.

Update on ongoing initial applications

2.6.1.

Axicabtagene ciloleucel – Orphan - EMA/H/0004480 Kite Pharma UK Ltd; treatment of B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) Scope: timetable for assessment Action: for information

2.6.2.

Voretigene neparvovec - Orphan - EMEA/H/C/0004451 Spark Therapeutics Ireland Ltd.; treatment of patients with vision loss due to leber congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy Scope: timetable for assessment Action: for information

2.7.

New applications No items

2.8.

Withdrawal of initial marking authorisation application No items

2.9.

Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 No items

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 6/17

2.10.

GMP and GCP inspections requests

2.11.

Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1.

Zalmoxis – allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex in virus thymidine kinase (hsv-tk mut2) – Orphan EMEA/H/C/002801/II/0005/G MolMed SpA; adjunctive treatment in haploidentical haematopoietic stem cell transplantation of adult patients with high-risk haematological malignancies Rapporteur: Hans Ovelgönne; CHMP Coordinator: Paula Boudewina van Hennik Scope: Quality Action: timetable for adoption

2.12. 2.12.1.

Other Post-Authorisation Activities Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence Orphan - EMEA/H/C/003854/REC/010 GlaxoSmithKline Trading Services Limited Rapporteur: Christiane Niederlaender, CHMP Coordinator: Robert James Hemmings Scope: Quality: Action: for information

3.

Certification of ATMPs Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1.

Opinion No items

3.2.

Day 60 Evaluation Reports No items

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 7/17

3.3.

New Applications

4.

Scientific Recommendation on Classification of ATMPs

4.1.

New requests – Appointment of CAT Coordinator

4.1.1.

Allogenic cardiopoietic cells derived from adipose tissue derived stem cells (ADSC) purified from healthy donor’s lipoaspirate – H0004911 Intended to help post - yocardial infarction patients in restoring cardiac function by targeting for repair the underlying myocardium damage Scope: appointment of CAT Coordinator and adoption of timetable Action: for adoption

4.1.2.

Recombinant adeno-associated virus serotype 2/1 vector encoding human βhexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta) – H0004906 Intended for the treatment of Tay-Sachs disease & Sandhoff disease monosialic ganglioside 2 (GM2) gangliosidosis Scope: appointment of CAT Coordinator and adoption of timetable Action: for adoption

4.1.3.

Adeno-associated virus (AAV) vector serotype 8 expressing human low-density lipoprotein receptor (hLDLR) - H0004905 Intended for the treatment of hypercholesterolaemia caused by homozygous mutations in the low density lipoprotein receptor (LDLR) gene Scope: appointment of CAT Coordinator and adoption of timetable Action: for adoption

4.1.4.

Skin tissue – H0004907 Intended for the treatment of patients with acute complex skin loss Scope: appointment of CAT Coordinator and adoption of timetable Action: for adoption

4.1.5.

Autologous CD34+ cells, freshly isolated – H000 Cells will be used to contribute the regeneration of soft and hard tissues of temporomandibular joints through their immunological action Scope: appointment of CAT Coordinator and adoption of timetable Action: for adoption

4.1.6.

Autologous dental pulp stem cells (DPSC), freshly isolated – H000 Intended for the regeneration of soft and hard tissues of temporomandibular joints

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 8/17

Scope: appointment of CAT Coordinator and adoption of timetable Action: for adoption

4.1.7.

Cultured dental pulp stem cells (DPSC) – H000 Intended for the regeneration of soft and hard tissues of temporomandibular joints Scope: appointment of CAT Coordinator and adoption of timetable Action: for adoption

4.2.

Day 30 ATMP scientific recommendation

4.2.1.

Allogeneic human glial-restricted precursors - H0004887/0001 Intended for the treatment of amyotrophic lateral sclerosis Scope: scientific recommendation Action: for adoption

4.2.2.

Allogeneic human glial-restricted precursors - H0004898/0001 Intended for the treatment of spinal cord injuries Scope: scientific recommendation Action: for adoption ribonucleic acid (RNA) molecules small interfering

4.2.3.

Nuclease-resistant, synthetic double-stranded, small interfering ribonucleic acid (siRNA) designed to temporarily inhibit the expression of the collagen-specific chaperone, heat shock protein 47 (HSP47) - H0004900/0001 Intended for the treatment of hepatic fibrosis Scope: scientific recommendation Action: for adoption

4.2.4.

Messenger RNA encoding immunostimulatory proteins constitutively active Toll-like receptor 4 (caTLR4), cluster of differentiation 40 ligand (CD40L) and cluster of differentiation 70 (CD70) and tumour associated antigens (TAA) tyrosinase, gp100, MAGE A3, MAGE C2 and PRAME - H0004899/0001 Intended for the treatment of melanoma Scope: scientific recommendation Action: for adoption

4.2.5.

Cultured viable chondrocytes in a 3-dimensional hydrogel - H0004901/0001 Intended for the treatment of articular cartilage defect of the knee Scope: scientific recommendation Action: for adoption

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 9/17

4.3.

Day 60 revised scientific recommendation (following list of questions) No items

4.4.

Finalisation of procedure No items

4.5.

Follow-up and guidance No items

5.

Scientific Advice Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1.

New requests – appointment of CAT Rapporteurs

5.2.

CAT reports

5.3.

List of Issues

5.4.

Finalisation of SA procedures

6.

Pre-Authorisation Activities Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1.

Pediatric investigation plans

6.2.

ITF briefing meetings in the field of ATMPs No items

6.3.

Priority Medicines (PRIME) – Eligibility requests

6.3.1.

Month 0 - Start of the procedure

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 10/17

6.3.2.

Month 1 – Discussion of eligibility

6.3.3.

Month 2 – Recommendation of eligibility

6.3.4.

Month 3 – Nomination of Rapporteurs

7.

Organisational, regulatory and methodological matters

7.1.

Mandate and organisation of the CAT

7.1.1.

Strategic Review & Learning meeting – Tallinn, Estonia, 15-17 November 2017 CAT Strategic Review & Learning meeting (SRLM) will take place in Tallinn, Estonia on 15-17 November 2017 under the auspices of the Estonian Presidency of the Council of the European Union CAT: Toivo Maimets, Martina Schüßler-Lenz Scope: topics for the first draft of the programme Action: for discussion

7.1.2.

Multinational Assessment Team (MNAT) concept: the next phase – broadening the concept to the post-authorisation phase Scope: broadening the concept to the post-authorisation phase Action: For information Note: the broadening of the MNAT concept to post-authorisation was adopted by EMA Management Board in December 2016.

7.2.

Coordination with EMA Scientific Committees

7.2.1.

Committee for Medicinal Products for Human Use (CHMP) Scope: Summary of Outcomes (SoO) for 14-17 August 2017 Written Procedure Action: for information

7.2.2.

Pharmacovigilance Risk Assessment Committee (PRAC) Scope: comments on post consultation on ‘Guideline on good pharmacovigilance practices (GVP), Module XV – Safety communication (Rev 1)’ should be sent by 18 September 2017 Action: for information

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 11/17

7.3.

Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1.

Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP) Scope: -Report on the workshop on personalised medicines -Draft agenda AMR workshop - 19 September 2017 -Draft agenda PCWP-HCPWP – 20 September 2017 Action: for information

7.4.

Cooperation within the EU regulatory network No items

7.5.

Cooperation with international regulators

7.5.1.

ATMP cluster teleconference with FDA, Health Canada and PMDA CAT: Martina Schüßler-Lenz Scope: draft agenda Action: for adoption

7.6.

CAT work plan

7.6.1.

Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London CAT: Martina Schüßler-Lenz Scope: feedback on the expert meeting that will take place on the first day of the CAT, 6 September 2017 Action: for information

7.6.2.

Expert meeting on genome editing, 18 October 2017, EMA, London CAT: Paolo Gasparini Scope: updated agenda Action: for information This meeting is open to all CAT members. Alternatively, members can join virtually (via Adobe Connect application).

7.6.3.

CAT 2017 work plan Scope: status of the CAT work plan Action: for information Note: Work plan was adopted via written procedure on 22 March 2017

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 12/17

7.6.4.

CAT 2018 work plan Scope: proposals for the CAT work plan 2018 Action: for discussion

7.7.

Planning and reporting

7.7.1.

Update on ongoing ATMP-related activities CAT: Martina Schüßler-Lenz Scope: at the publication on 2 February 2017 of the document ‘Issues identified by stakeholders: follow-up from EMA’s ATMP workshop’, the development of a broader EU plan, prepared jointly by EMA, CAT, the European Commission and the National Competent Authorities was announced. CAT members are asked for their contributions and input. Two documents are tabled: the ‘List of proposed actions to improve the regulatory framework for ATMPs’ from the Commission and an EMA working document (based on the above mentioned document published in February 2017) ‘Update on ongoing ATMP-related activities’. Action: for discussion

7.8.

Others

7.8.1.

Interaction with EBMT Proposal for a meeting with EBMT in the margins of the December 2017 CAT meeting, with the involvement of PRAC members, to discuss amongst others, a common protocol for registries for CAR-T cells CAT: Martina Schüßler-Lenz Action: for discussion

8.

Any other business No items Date of next CAT meeting: 04-06 October 2017

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 13/17

9.

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda. Abbreviations / Acronyms AR: Assessment Report ATMP: Advanced Therapy Medicinal Product BWP: Biologics Working Party CAT: Committee for Advanced Therapies CHMP: Committee for Medicinal Product for Human Use COMP: Committee for Orphan Medicinal Products CTFG: Clinical Trial Facilitation Group DG: Drafting Group EC: European Commission ERA: Environmental Risk Assessment FDA: Food and Drug Administration FL: Final Letter GCP: Good Clinical Practice GLP: Good Laboratory Practice GMO: Genetically-modified organism GMP: Good Manufacturing Practice HTA: Health Technology Assessment Bodies HSPC: Hematopoietic Stem and Progenitor Cells ITF: Innovative Task Force JR: Joint Report LoOI: List of outstanding issues LoQ: List of questions MA: Marketing Authorisation MAA: Marketing Authorisation Applicant MAH: Marketing Authorisation Holder MSC: Mesenchymal stem cells PDCO: Paediatric Committee PMDA: Pharmaceuticals and Medical Devices Agency (Japan) PIP: Paediatric Investigation Plan PL: Package leaflet PRAC: Pharmacovigilance and Risk Assessment Committee # PRIME: Priority Medicines RMP: Risk Management Plan RP: Reflection paper RSI: Request for supplementary information SAs: Scientific Advices Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 14/17

SAG-O: Scientific Advisory Group Oncology SAWP: Scientific Advice Working Party SR: Summary Report SWP: Scientific Working Party SME: Small and medium size enterprises SmPC: Summary of Products Characteristics TT: Timetable Evaluation of ATMPs (section 2) This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10). New applications (sections 2.1. to 2.12.) Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here. The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications. Oral explanation (section 2.2.) Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee. Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person. Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.) This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion,

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 15/17

which is transmitted to the CHMP for final adoption. Withdrawal of applications (section 2.7.) This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary. New applications (section 2.9.) In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications. GMP and GCP Inspections Issues (section 2.10.) This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP). Post-authorisation activities (section 2.12.) This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, reexamination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here. Certification of ATMPs (section 3) This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here. Scientific Recommendation on Classification of ATMPs (Section 4) This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here. Scientific Advice (section 5) This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here. Pre-Authorisation (section 6) Paediatric Investigation Plan (PIP) This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days. CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda. Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 16/17

ITF Briefing meeting in the field of ATMPs This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here. Priority Medicines (PRIME) This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP. CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP. Organisational, regulatory and methodological matters (section 7) This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups. Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties. Any other business (section 8) This section is populated with miscellaneous topics not suitable under the previous headings. More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

Committee for Advanced Therapies (CAT) EMA/CAT/549745/2017

Page 17/17

Agenda - European Medicines Agency - Europa EU

Sep 8, 2017 - Orphan - EMEA/H/C/003854/REC/010. GlaxoSmithKline Trading Services Limited. Rapporteur: Christiane Niederlaender, CHMP Coordinator: ...

224KB Sizes 0 Downloads 81 Views

Recommend Documents

Agenda - European Medicines Agency - Europa EU
Nov 3, 2016 - Scope: 'Optimising the development of ATMPs to meet patient needs' ... the CAT would like to discuss with company representatives in person.

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - under Article 107i of Directive 2001/83/EC, based on pharmacovigilance data. Action: For adoption of ..... manufacturing process; and 3) removal of the following missing information: special patient groups. Action: For .... analysis of

Agenda - European Medicines Agency - Europa EU
4 days ago - Meningococcal group A, C, W135 and Y conjugate vaccine - NIMENRIX (CAP) -. EMEA/H/C/002226/II/0078 . ...... Applicant: AstraZeneca AB.

Agenda - European Medicines Agency - Europa EU
Jul 31, 2017 - Human Medicines Research and Development Support Division. Agenda ... use of such prior knowledge in regulatory application dossiers, to support manufacturing and control strategies ... of accelerated access schemes.

Agenda - European Medicines Agency - Europa EU
Oct 26, 2016 - (as Web sites for social networking and microblogging) through which ... 09:10. Opening remarks. D. Haerry (PCWP)/. G. Calvo (HCPWP). 1.

Agenda - European Medicines Agency - Europa EU
Nov 27, 2017 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be